A case report: Immune responses and clinical course of the first human use of granulocyte/macrophage-colony-stimulating-factor-transduced autologous melanoma cells for immunotherapy

Cancer Immunology Immunotherapy

Volumn 44, Issue 1, 1997, Pages 10-20

  Ellem, Kay A O ^a   O'Rourke, Michael G E ^b   Johnson, Gregory R ^a   Parry, Gordon ^d   Misko, Ihor S ^a   Schmidt, Christopher W ^a   Parsons, Peter G ^a   Burrows, Scott R ^a   Cross, Simone ^a   Fell, Andrew ^a   Li, Chung Leung ^a   Bell, John R ^b   Dubois, Philip J ^c   Moss, Denis J ^a   Good, Michael F ^a   Kelso, Anne ^a   Cohen, Lawrence K ^d   Dranoff, Glenn ^e   Mulligan, Richard C ^d,f  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b Raymond Terrace   (Australia)

^c Mater Private Hospital Brisbane   (Australia)

^d CELL GENESYS INC   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

C reactive protein; cerebral metastases acute cerebral oedema; eosinophilia; GM CSF transduced autologous melanoma vaccine; tumour reactive cytotoxic T lymphocytes

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MELANOMA VACCINE;

ADULT; ARTICLE; CASE REPORT; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; HUMAN; IMMUNOTHERAPY; INTRADERMAL DRUG ADMINISTRATION; MALE; MELANOMA; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; VACCINATION;

AUTOPSY; BIOLOGICAL MARKERS; BRAIN NEOPLASMS; C-REACTIVE PROTEIN; CD4-POSITIVE T-LYMPHOCYTES; EOSINOPHILIA; GENE TRANSFER TECHNIQUES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; HYPERSENSITIVITY, DELAYED; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; T-LYMPHOCYTES, CYTOTOXIC; TRANSDUCTION, GENETIC; TRANSPLANTATION, AUTOLOGOUS; VACCINATION;

EID: 0012201556     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050349     Document Type: Article

References (48)

1. Arinaga S, Karimine N, Takamuku K, Nanbara S, Inoue H, Abe R, Watanabe D, Matsuoka H, Ueo H, Akiyoshi T (1992) Correlation of eosinophilia with clinical response in patients with advanced carcinoma treated with low-dose recombinant interleukin-2 and mitomycin C. Cancer Immunol Immunother 35:246
2. Barth A, Hoon DSB, Foshag LJ, Nizze JA, Famatiga E, Okun E, Morton DL (1994) Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response. Cancer Res 54:3342
3. Baumann H, Gauldie J (1994) The acute phase response. Immunol Today 15:74
4. Berd D, Maguire HC JR, McCue P, Mastrangelo MJ (1990) Treatment of metastatic melanoma with an autologous tumour-cell vaccine: clinical and immunologic results in 64 patients. J Clin Oncol 8:1858
5. Burton RC, Coates MS, Hersey P, Roberts G, Chetty MP, Chen S, Hayes MH, Howe CG, Armstrong BK (1993) An analysis of a melanoma epidemic. Int J Cancer 55:765
6. Chen O, Daniel V, Maher DW, Hersey P (1994) Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int J Cancer 56:755
7. Chihara J, Plumas J, Gruart V, Tavernier J, Prin L, Capron A, Capron M (1990) Characterisation of a receptor for interleukin 5 on human eosinophils: variable expression and induction by granulocyte/macrophage colony-stimulating factor. J Exp Med 172:1347
8. Colombo MP, Forni G (1994) Cytokine gene transfer in tumour inhibition and tumour therapy: where are we now? Immunol Today 15:48
9. Corrigan CJ, Kay AB (1992) T cells and eosinophils in the pathogenesis of asthma. Immunol Today 13:501
10. De Groen PC, Kephart GM, Gleich GJ, Ledwig J (1994) The eosinophil as an effector cell of the immune response during hepatic allograft rejection. Hepatology 20:654
11. Dranoff G, Jaffee E, Lazenby A, Golumbeck P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC (1993) Vaccination with irradiated tumour cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and lone-lasting anti-tumour immunity. Proc Natl Acad Sci USA 90:3539
12. Foster PF, Sankar HN, Hart M, Ashmann M, Williams JW (1989) Blood and graft eosinophilia as predictors of rejection in human liver transplantation. Transplantation 47:72
13. Glickstein LJ, Huber BT (1995) Karoushi-death by overwork in the immune system. J Immunol 155:522
14. Good MF, Boyd AW, Nossal GJV (1983) Analysis of true antihapten cytotoxic clones in limit dilution microcultures after correction for "anti-self" activity: precursor frequencies. Ly-2 and Thy-1 phenotype, specificity, and statistical methods J Immunol 130:2046
15. Herr W, Wölfel T, Heike M, Meyer Zum Büschenfelde K-H, Knuth A (1994) Frequency analysis of tumour-reactive cytotoxic T lymphocytes in peripheral blood of a melanoma patient vaccinated with autologous tumour cells. Cancer Immunol Immunother 39:93
16. Huang AYC, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll DM, Levitsky H (1994) The role of hone marrow derived cells in presenting MHC class I-restricted tumour antigens. Science 264:961
17. Huang AYC, Bruce AT, Pardoll DM, Levitsky HI (1996) Does B7-1 expression confer antigen-presenting cell capacity to tumours in vivo? J Exp Med 183:769
18. Jaffee EM, Dranoff G, Cohen LK, Hauda KM, Clift S, Marshall FF, Mulligan RC, Pardoll DM (1993) High efficiency gene transfer into primary human tumour explants without cell selection. Cancer Res 53:2221
19. Jelfs P, Giles G, Shugg D, Taylor R, Bonett A, Thompson J, Ring I, Durling G (eds) (1992) Cancer in Australia 1983-1985. Australian Institute of Health and Welfare, AGPS, Canberra
20. Kormendi F, Amend WJC (1988) The importance of eosinophil cells in kidney allograft rejection. Transplantation 45:537
21. Krüger-Krasagakes S, Li W, Richter G, Diamantstein T, Blankenstein T (1993) Eosinophils infiltrating interleukin-5 gene-transfected tumours do not suppress tumour growth. Eur J Immunol 23:992
22. + HLA-class-I-restricted cytotoxic T cell clones with long-term assays and pretreatment of targets with interferon γ. Cancer Immunol Immunother 37:187
23. Loeb LA (1991) Mutator phenotype may be required for multistage carcinogenesis. Cancer Res 51:3075
24. Loeb LA (1994) Microsatellite instability: marker of a mutator phenotype in cancer. Cancer Res 54:5059
25. Mackensen A, Ferradini L, Carcelain G, Triebel F, Faure F, Viel S, Hercend T (1993) Evidence for in situ amplification of cytotoxic T-lymphocytes with antitumour activity in a human regressive melanoma. Cancer Res 53:3569
26. MacLennan R, Green AC, Mcleod GRC, Martin NG (1992) Increasing incidence of cutaneous melanoma in Queensland, Australia. J Natl Cancer Inst 84:1427
27. Macphee DG (1995) Mismatch repair, somatic mutations, and the origins of cancer. Cancer Res 55:5489
28. Martinez OM, Krams SM, Sterneck M, Villanueva JC, Falco DA, Ferrell LD, Lake J, Roberts JP, Ascher NL (1992) Intragraft cytokine profile during human liver allograft rejection. Transplantation 53:449
29. Martinez OM, Ascher NL, Ferrell L, Villanueva J, Lake J, Roberts JP, Krams SM (1993) Evidence for a nonclassical pathway of graft rejection involving interleukin 5 and eosinophils. Transplantation 5:909
30. Mattei S, Colombo MP, Melani C, Silvani A, Parmiani G, Herlyn M (1994) Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes. Int J Cancer 56:853
31. Matzinger P (1994) Tolerance, danger, and the extended family. Annu Rev Immunol 12:991
32. Mazzocchi A, Belli F, Mascheroni L, Vegetti C, Parmiani G, Anichini A (1994) Frequency of cytotoxic T lymphocyte precursors (CTLp) interacting with autologous tumour via the T-cell receptor: Limiting dilution analysis of specific CTLp in peripheral blood and tumour-invaded lymph nodes of melanoma patients. Int J Cancer 58:330
33. Misko IS, Pope JH, Hutter R, Soszynski TD, Kane RG (1984) HLA-DR-antigen-associated restriction of EBV-specific cytotoxic T-cell colonies. Int J Cancer 33:239
34. Modesti A, Masuelli L, Modica A, D'Orazi G, Scarpa S, Bosco MC, Fornig G (1993) Ultrastructural evidence of the mechanisms responsible for interleukin-4-activated rejection of a spontaneous murine adenocarcinoma. Int J Cancer 53:988
35. Morton DL, Foshag LJ, Hoon, DSB, Nizze JA, Famatiga E, Wanek LA, Chang C, Davtyan DG, Gupta RK, Elashoff R (1992) Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 216:463
36. Moss DJ, Pope JH (1975) EB virus-associated nuclear antigen production and cell proliferation in adult peripheral blood leukocytes inoculated with the QIMR-WIL strain of EB virus. Int J Cancer 15:503
37. Platt JL, Grant BW, Eddy AA, Michael AF (1983) Immune cell populations in cutaneous delayed type hypersensitivity. J Exp Med 158:1227
38. Ring IT, Walker SM, Firman D, Bonett A, Roder D (1989) Melanoma in Queensland. Trans Menzies Found 15:157
39. Rosenberg SA, Anderson WF, Blaese M, Hwu P, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Ettinghausen SE (1993) The development of gene therapy for the treatment of cancer. Ann Surg 218:455
40. Schmidt CW, Burrows SR, Sculley TB, Moss DJ, Misko IS (1991) Nonresponsiveness to an immunodominant Epstein-Barr virus-encoded cytotoxic T-lymphocyte epitope in nuclear antigen 3A: implications for vaccine strategies. Proc Natl Acad Sci USA 88:9478
41. Spry CJF, Kay AB, Gleich GJ (1992) Eosinophils 1992. Immunol Today 13:384
42. Taga K, Tosato G (1992) IL-10 inhibits human T cell proliferation and IL-2 production. J Immunol 148:1143
43. Tepper RI, Coffman R, Leder P (1992) An eosinophil-dependent mechanism for the anti-tumour effect of interleukin-4. Science 257:548
44. Turk JL (1975) Delayed hypersensitivity, 2nd edn (revised). North Holland, Oxford, p 53
45. Wang H, Nanra RS, Stein A, Avis L, Price A, Hibberd AD (1994) Eosinophils in acute renal allograft rejection. Transplant Immunol 2:41
46. Weir MR, Hall-Craggs M, Shen SY, Posner JN, Alongi SV, Dagher FJ, Sadler JH (1986) The prognostic value of the eosinophil in acute renal allograft rejection. Transplantation 41:709
47. Westermann J, Pabst R (1990) Lymphocyte subsets in the blood: a diagnostic window on the lymphoid system? Immunol Today 11:406
48. Whitehead AS, Steel DM (1994) The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunol Today 15:81